Bradykinin B(2) receptor antagonism attenuates blood pressure response to acute angiotensin-converting enzyme inhibition in normal men

What Was Tested

The paper reports a study of Bradykinin in the context of low blood pressure and orthostatic hypotension, published as a randomized controlled trial.

The physiological effects of angiotensin-converting enzyme (ACE) inhibition may be in part mediated by bradykinin.

The researchers investigated the effect of coadministration of the specific bradykinin B(2) receptor antagonist icatibant on hemodynamic and neurohormonal responses to acute intravenous ACE inhibition in normal men on a normal sodium diet.

Who Took Part

According to the abstract, 12 volunteers were involved.

The age groups tagged for this paper are adults, men only.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Bradykinin and who got the comparison, which limits bias.

As a double-blind Bradykinin study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Bradykinin group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Angiotensin-Converting Enzyme Inhibitors, Angiotensins, Area Under Curve, Blood Pressure, Bradykinin, Bradykinin Receptor Antagonists and Peptidyl-Dipeptidase A.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Bradykinin in 12 volunteers in people with low blood pressure and orthostatic hypotension.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2000 (Hypertension (Dallas, Tex. : 1979)), a journal based in United States.

More context: the Bradykinin compound page, Low blood pressure and orthostatic hypotension research.